Cat. No. | Product name | CAS No. |
DC7544 |
CUDC-101
Featured
CUDC-101 is a potent multi-targeted inhibitor against HDAC, EGFR and HER2 with IC50 of 4.4 nM, 2.4 nM, and 15.7 nM, and inhibits class I/II HDACs, but not class III, Sir-type HDACs. Phase 1. |
1012054-59-9 |
DC7810 |
CX-5461
Featured
CX-5461 is an inhibitor of rRNA synthesis, selectively inhibits Pol I-driven transcription of rRNA, has no effect on Pol II, and possesses 250-to 300-fold selectivity for inhibition of rRNA transcription versus DNA replication and protein translation. |
1138549-36-6 |
DC8404 |
E3330
Featured
E3330 is a potent and selective APE1(Ref-1) inhibitor, which suppressed NF-kappa B DNA-binding activity. |
136164-66-4 |
DC7128 |
Lucitanib(E3810)
Featured
E-3810 is a novel dual inhibitor targeting human vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs) with antiangiogenic activity. |
1058137-23-7 |
DC10563 |
E-7046
Featured
E7046 is an orally bioavailable and specific EP4 antagonist, with IC50 of 13.5 nM and Ki of 23.14 nM, exhibiting anti-tumor activities. |
1369489-71-3 |
DC11062 |
E7107
E7107 (E-7107) is a derivative of pladienolide that targets the SF3b subunit of the spliceosome, shows significant antitumor activity in vitro and in vivo. |
630100-90-2 |
DC8489 |
ETC-159
Featured
ETC-159 is a potent and specific inhibitor of Wnt secretion. ETC-159 inhibits _beta_-catenin reporter activity in a dose-dependent manner with an IC50 of 2.9 nM. |
1638250-96-0 |
DC9515 |
PI3K inhibitor GS1059615
GSK1059615 is a dual inhibitor of PI3Kα/β/δ/γ (reversible) and mTOR with IC50 of 0.4 nM/0.6 nM/2 nM/5 nM and 12 nM, respectively. |
958852-01-2 |
DC7141 |
Omipalisib
Featured
GSK2126458 is a highly selective and potent inhibitor of PI3K with Ki of 0.019 nM/0.13 nM/0.024 nM/0.06 nM and 0.18 nM/0.3 nM for p110α/β/δ/γ, mTORC1/2 , respectively. |
1086062-66-9 |
DC7812 |
GSK923295
Featured
GSK923295 is a first-in-class, specific allosteric inhibitor of CENP-E kinesin motor ATPase with Ki of 3.2 nM, and less potent to mutant I182 and T183. |
1088965-37-0 |
DC8768 |
HMN-214
Featured
HMN-214(IVX214) is a potent PLK1 inhibitor an average IC50 of 0.12 μM. |
173529-46-9 |
DC11303 |
CT7001 hydrochloride
Featured
ICEC0942 is a selective CDK7 inhibitor, with IC50s of 41 nM and 578 nM for CDK7/CycH/MAT1 and CDK2/cycE1, respectively. |
1805789-54-1 |
DC10918 |
INCB053914
INCB053914 (INCB-053914) is a novel potent, and selective ATP-competitive, pan-PIM kinase inhibitor with IC50 of 0.24/30.0/0.12 nM for PIM1/2/3, respectively. |
1620012-39-6 |
DC9829 |
IPI-549
Featured
IPI-549 is an orally administered immuno-oncology development candidate that selectively inhibits PI3K-gamma. |
1693758-51-8 |
DC7177 |
JNJ 38877605
Featured
JNJ-38877605 is an ATP-competitive inhibitor of c-Met with IC50 of 4 nM, 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases. |
943540-75-8 |
DC10487 |
KO947
Featured
KO-947 is a small molecule inhibitor of extracellular-signal-regulated kinases 1 and 2 (ERK1/2), as a potential treatment for cancers in which the mitogen activated protein kinase (MAPK) pathway. |
1695533-89-1 |
DC9788 |
KP1019(FFC14A)
KP1019 (FFC14A) is just the second ruthenium-based anticancer agent after NAMI-A which was developed to the stage of clinical trials. |
124875-20-3 |
DC10454 |
KRN633
Featured
KRN633 is a potent and selective VEGFR inhibitor. which inhibits tyrosine phosphorylation of VEGFR-2 (IC50 = 1.16 nmol/L) in human umbilical vein endothelial cells. |
286370-15-8 |
DC8023 |
KX2-391
Featured
KX2-391, the first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines. |
897016-82-9 |
DC7943 |
LYS6K2(LY2584702) tosylate salt
Featured
LY-2584702 is an orally available inhibitor of p70S6K signaling; inhibits p70S6K and prevents phosphorylation of the S6 subunit of ribosomes. |
1082949-68-5 |
DC10675 |
LY3200882
Featured
LY3200882 is a novel, highly selective TGFβRI small molecule inhibitor. |
1898283-02-7 |
DC12261 |
LY3295668 (AK-01)
LY3295668 is a potent, orally active and highly specific Aurora-A kinase inhibitor, with Ki values of 0.8 nM and 1038 nM for AurA and AurB, respectively. |
1919888-06-4 |